C-reactive protein in atherosclerosis: A causal factor?

[1]  C. Sabin,et al.  Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself , 2005, Circulation research.

[2]  O. Wagner,et al.  Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. , 2005, European heart journal.

[3]  L. Marnell,et al.  C-reactive protein: ligands, receptors and role in inflammation. , 2005, Clinical immunology.

[4]  U. Singh,et al.  C-Reactive Protein Decreases Tissue Plasminogen Activator Activity in Human Aortic Endothelial Cells: Evidence that C-Reactive Protein Is a Procoagulant , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[5]  C. Wanner,et al.  Native C-Reactive Protein Increases Whereas Modified C-Reactive Protein Reduces Atherosclerosis in Apolipoprotein E–Knockout Mice , 2005, Circulation.

[6]  M. Blettner,et al.  Role of C-Reactive Protein in Atherogenesis: Can the Apolipoprotein E Knockout Mouse Provide the Answer? , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Lumsden,et al.  C-reactive protein decreases expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. , 2005, Surgery.

[8]  G. O’Keefe,et al.  Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. , 2005, The Journal of clinical endocrinology and metabolism.

[9]  J. Jukema,et al.  No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Arjun Deb,et al.  Proapoptotic, Antimigratory, Antiproliferative, and Antiangiogenic Effects of Commercial C-Reactive Protein on Various Human Endothelial Cell Types In Vitro: Implications of Contaminating Presence of Sodium Azide in Commercial Preparation , 2005, Circulation research.

[11]  T. D. Du Clos,et al.  Binding and Internalization of C-Reactive Protein by Fcgamma Receptors on Human Aortic Endothelial Cells Mediates Biological Effects , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[12]  M. Pepys.  CRP or not CRP? That is the question. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[13]  J. Giddings,et al.  C-Reactive Protein–Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[14]  P. Reitsma,et al.  Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans , 2005, Circulation research.

[15]  J. Tune,et al.  C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. , 2005, American journal of physiology. Heart and circulatory physiology.

[16]  M. Singer,et al.  Inflammation and Endothelial Function: Direct Vascular Effects of Human C-Reactive Protein on Nitric Oxide Bioavailability , 2005, Circulation.

[17]  L. Rodríguez-Mañas,et al.  Evidence for Sodium Azide as an Artifact Mediating the Modulation of Inducible Nitric Oxide Synthase by C-Reactive Protein , 2005, Journal of cardiovascular pharmacology.

[18]  A. Testa,et al.  How to use the C-reactive protein in cardiac disease? , 2005, Minerva cardioangiologica.

[19]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[20]  J. Kemp,et al.  Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  T. Sawamura,et al.  C-Reactive Protein Enhances LOX-1 Expression in Human Aortic Endothelial Cells: Relevance of LOX-1 to C-Reactive Protein–Induced Endothelial Dysfunction , 2004, Circulation research.

[22]  R. Lin,et al.  C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. , 2004, Biological & pharmaceutical bulletin.

[23]  D. Lang,et al.  C-Reactive Protein-Induced In Vitro Vasorelaxation Is an Artefact Caused by the Presence of Sodium Azide in Commercial Preparations , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[24]  E. Fleck,et al.  C-Reactive Protein Induces Apoptosis in Human Coronary Vascular Smooth Muscle Cells , 2004, Circulation.

[25]  F. Burzotta,et al.  Inflammation as a Possible Link Between Coronary and Carotid Plaque Instability , 2004, Circulation.

[26]  Seung‐Jung Park,et al.  C-Reactive Protein Promotes Monocyte Chemoattractant Protein-1–Mediated Chemotaxis Through Upregulating CC Chemokine Receptor 2 Expression in Human Monocytes , 2004, Circulation.

[27]  J. Gamble,et al.  High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity , 2004, Circulation.

[28]  E. Paffen,et al.  C-Reactive Protein Does Not Directly Induce Tissue Factor in Human Monocytes , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[29]  S. Verma,et al.  C-Reactive Protein: Structure Affects Function , 2004, Circulation.

[30]  J. Filep,et al.  Conformational Rearrangement in C-Reactive Protein Is Required for Proinflammatory Actions on Human Endothelial Cells , 2004, Circulation.

[31]  P. Libby,et al.  Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. , 2004, The American journal of medicine.

[32]  K. Hatakeyama,et al.  Possible contribution of C-reactive protein within coronary plaque to increasing its own plasma levels across coronary circulation. , 2004, The American journal of cardiology.

[33]  S. Devaraj,et al.  Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. , 2004, Journal of molecular and cellular cardiology.

[34]  K. Kitamura,et al.  Effects of C-reactive protein on atherogenic mediators and adrenomedullin in human coronary artery endothelial and smooth muscle cells. , 2004, Biochemical and biophysical research communications.

[35]  Lan Li,et al.  C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice , 2004, Circulation.

[36]  P. Ridker,et al.  C-reactive protein and the risk of developing hypertension. , 2003, JAMA.

[37]  S. Verma,et al.  C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. , 2003, The Journal of thoracic and cardiovascular surgery.

[38]  V. Mujica,et al.  A Simple Theoretical Model to Study the Voltage Dependence of the Electronic Structure of Phenyl Ethylene Oligomers , 2003, Annals of the New York Academy of Sciences.

[39]  K. Shimada,et al.  C-Reactive Protein Directly Inhibits Nitric Oxide Production by Cytokine-stimulated Vascular Smooth Muscle Cells , 2003, Journal of cardiovascular pharmacology.

[40]  E. Yeh,et al.  Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.

[41]  S. Devaraj,et al.  C-Reactive Protein Decreases Prostacyclin Release From Human Aortic Endothelial Cells , 2003, Circulation.

[42]  E. Edelman,et al.  Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice , 2003, Circulation.

[43]  Petr Jarolim,et al.  Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones , 2003, Circulation.

[44]  S. Verma,et al.  C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle , 2003, Circulation.

[45]  N. Brot,et al.  Opsonization of Apoptotic Cells and Its Effect on Macrophage and T Cell Immune Responses , 2003, Annals of the New York Academy of Sciences.

[46]  Y. Hattori,et al.  Vascular smooth muscle cell activation by C-reactive protein. , 2003, Cardiovascular research.

[47]  S. Devaraj,et al.  C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis , 2003, Circulation.

[48]  K. Shimada,et al.  Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. , 2003, The American journal of cardiology.

[49]  Nancy R Cook,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. , 2002, The New England journal of medicine.

[50]  K. Woollard,et al.  Direct modulatory effect of C‐reactive protein on primary human monocyte adhesion to human endothelial cells , 2002, Clinical and experimental immunology.

[51]  J. Witztum,et al.  C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Sridevi Devaraj,et al.  Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells , 2002, Circulation.

[53]  G. Lip,et al.  Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[54]  E. Topol,et al.  Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. , 2001, Circulation research.

[55]  J. Willerson,et al.  Modulation of C-Reactive Protein-Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs , 2001, Circulation.

[56]  P. Libby,et al.  Inflammation and thrombosis: the clot thickens. , 2001, Circulation.

[57]  V. Hombach,et al.  C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis , 2001, Circulation.

[58]  P. Mcgeer,et al.  Generation of C-reactive protein and complement components in atherosclerotic plaques. , 2001, The American journal of pathology.

[59]  S. Ranganathan,et al.  Multiple ligand binding sites on domain seven of human complement factor H. , 2001, International immunopharmacology.

[60]  M. Pepys,et al.  C-reactive protein and atherothrombosis. , 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.

[61]  N. Mackman,et al.  LPS induction of gene expression in human monocytes. , 2001, Cellular signalling.

[62]  N. Brot,et al.  C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response , 2000, The Journal of experimental medicine.

[63]  F. Rosendaal,et al.  C‐reactive protein, cardiovascular risk factors and the association with myocardial infarction in men , 2000, Journal of internal medicine.

[64]  W. Koenig,et al.  C-Reactive Protein in the Arterial Intima: Role of C-Reactive Protein Receptor–Dependent Monocyte Recruitment in Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[65]  J. Volanakis,et al.  Complement-Dependent Acute-Phase Expression of C-Reactive Protein and Serum Amyloid P-Component1 , 2000, The Journal of Immunology.

[66]  T. D. Du Clos,et al.  Function of C-reactive protein. , 2000 .

[67]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[68]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[69]  J. Radosevich,et al.  Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. , 2000, The American journal of the medical sciences.

[70]  V. Pasceri,et al.  Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. , 2000, Circulation.

[71]  T. D. Du Clos.  Function of C-reactive protein , 2000, Annals of medicine.

[72]  A. Whitehead,et al.  Serum amyloid A, the major vertebrate acute-phase reactant. , 1999, European journal of biochemistry.

[73]  V. Prochorov,et al.  Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: further evidence for smoldering inflammation in patients with atherosclerosis. , 1999, American heart journal.

[74]  D. Bharadwaj,et al.  The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II , 1999 .

[75]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[76]  J. Volanakis,et al.  C-Reactive Protein: Structural Biology and Host Defense Function , 1999, Clinical chemistry and laboratory medicine.

[77]  A. Sharrett,et al.  Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[78]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[79]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[80]  S. Bhakdi,et al.  Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[81]  W. Koenig,et al.  C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[82]  P. Ridker,et al.  Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. , 1998, Circulation.

[83]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[84]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[85]  S. Thompson,et al.  Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. , 1996, Circulation.

[86]  A. Roessner,et al.  Expression of the adhesion molecules ICAM, VCAM, and ELAM in the arteriosclerotic plaque. , 1996, General & diagnostic pathology.

[87]  J. Volanakis,et al.  Three dimensional structure of human C-reactive protein , 1996, Nature Structural Biology.

[88]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[89]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[90]  M. Brčić,et al.  Change in sensitivity to lipopolysaccharide during the differentiation of human monocytes to macrophages in vitro , 1994, Experientia.

[91]  G. Lozanski,et al.  Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. , 1992, Cytokine.

[92]  R. Crowell,et al.  C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. , 1991, Journal of immunology.

[93]  S. Coughlin,et al.  Monocyte chemoattractant protein-1 in human atheromatous plaques. , 1991, The Journal of clinical investigation.

[94]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[95]  P. Heinrich,et al.  Acute‐phase response of human hepatocytes: Regulation of acute‐phase protein synthesis by interleukin‐6 , 1990, Hepatology.

[96]  G. Hansson,et al.  Complement receptors and regulatory proteins in human atherosclerotic lesions. , 1989, Arteriosclerosis.

[97]  Reynolds Gd,et al.  C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. , 1987 .

[98]  L. Baum,et al.  Brief Definitive Report C-reactive Protein Is Produced by a Small Number of Normal Human Peripheral Blood Lymphocytes , 2022 .

[99]  W. Weston,et al.  The Endotoxin‐induced Coagulant Activity of Human Monocytes , 1975, British journal of haematology.

[100]  J. Volanakis,et al.  Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. , 1974, Journal of immunology.

[101]  Hans Michael Piper,et al.  Cardiovascular Research , 1966, British medical bulletin.

[102]  A. Gautier,et al.  C-reactive protein , 2005 .

[103]  Thomas Francis,et al.  SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS , 1930, The Journal of experimental medicine.

[104]  S. Devaraj,et al.  Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. , 2006, Atherosclerosis.

[105]  A. García-Méndez,et al.  Effect of C-reactive protein on Fcgamma receptor II in cultured bovine endothelial cells. , 2005, Clinical science.

[106]  D. Morrow,et al.  Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. , 2003, Reviews in cardiovascular medicine.

[107]  P. Libby,et al.  The CD40/CD154 receptor/ligand dyadRID="†"ID="†" Review , 2001, Cellular and Molecular Life Sciences CMLS.

[108]  S. Freedman,et al.  Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. , 2000, Circulation.

[109]  N. Brot,et al.  C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response: Implications for Systemic Autoimmunity , 2000 .

[110]  中込 明裕.  Interferon-γ and Lipopolysaccharide Potentiate Monocyte Tissue Factor Induction by C-Reactive Protein Relationship With Age, Sex, and Hormone Replacement treatment , 2000 .

[111]  P. Libby,et al.  Cytokines Regulate Vascular Functions Related to Stability of the Atherosclerotic Plaque , 1995, Journal of cardiovascular pharmacology.

[112]  B. Barna,et al.  Activation of human monocytes and alveolar macrophages by a synthetic peptide of C-reactive protein. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[113]  R. Vance,et al.  C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. , 1987, Archives of pathology & laboratory medicine.

[114]  E. Downs,et al.  Modulation of human monocyte chemotaxis and procoagulant activity by human C-reactive protein (CRP). , 1986, Lymphokine research.

[115]  B. Osterud.  Interaction of endotoxins, blood elements and the vessel wall. , 1985, Progress in clinical and biological research.